Abstract: The invention provides novel erythromycin derivatives in which methyl groups on the macrolactone ring have been substituted with —H, -Et, and/or —OH. The invention also provides reagents such as isolated polynucleotides, vectors comprising the polynucleotides and host cells transformed with the vectors for making the novel compounds. Methods for making the compounds utilizing genetic engineering techniques are also disclosed.

Abstract: The invention provides novel erythromycin derivatives in which methyl groups on the macrolactone ring have been substituted with —H, -Et, and/or —OH. The invention also provides reagents such as isolated polynucleotides, vectors comprising the polynucleotides and host cells transformed with the vectors for making the novel compounds. Methods for making the compounds utilizing genetic engineering techniques are also disclosed.

Abstract: The invention provides novel erythromycin derivatives in which methyl groups on the macrolactone ring have been substituted with --H, -Et, and/or --OH and the ethyl side-chain has been substituted with hydroxymethyl or dihydroxycyclohexylmethyl side-chains. The invention also provides reagents such as isolated polynucleotides, vectors comprising the polynucleotides and host cells transformed with the vectors for making the novel compounds. Methods for making the compounds utilizing genetic engineering techniques are also disclosed.

Abstract: The invention provides novel erythromycin derivatives in which methyl groups on the macrolactone ring have been substituted with --H, --Et, and/or --OH. The invention also provides reagents such as isolated polynucleotides, vectors comprising the polynucleotides and host cells transformed with the vectors for making the novel compounds. Methods for making the compounds utilizing genetic engineering techniques are also disclosed.

Abstract: A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the erythromycin C-12 and C-6 hydroxylases produces a mixture of 6,12-dideoxyerythromycin A and the precursor molecule, 6-deoxyerythromycin D. To achieve conversion of the precursor to the final product, a second copy of eryG is inserted into a non-essential region of the Sac. erythraea chromosome resulting in high purity 6,12-dideoxyerythromycin A.

Abstract: A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the erythromycin C-12 and C-6 hydroxylases produces a mixture of 6,12-dideoxyerythromycin A and the precursor molecule, 6-deoxyerythromycin D. To achieve conversion of the precursor to the final product, a second copy of eryG is inserted into a non-essential region of the Sac. erythraea chromosome resulting in high purity 6,12-dideoxyerythromycin A.

Abstract: A vector including a DNA sequence encoding a secretory signal sequence substantially identical to the secretory signal encoding sequence of the Bacillus licheniformis .alpha.-amylase gene; upstream from the signal-encoding sequence, a promoter sequence and a ribosome binding site sequence, transcription of the signal-encoding sequence being under the control of the promoter sequence; and downstream from the signal-encoding sequence, a site for the insertion into the vector of a heterologous DNA sequence, in reading frame with the signal-encoding sequence.